Xinhua Zhao, PhD

Opioid use incidence and prevalence rates decreased with implementation of an opioid safety initiative, whereas nonsteroidal anti-inflammatory drug rates remained constant. Rates of adverse events were higher among opioid users.

After the FDA warning and removal of rosiglitazone from the VA National Formulary, glucose control may have declined among those discontinuing rosiglitazone without receiving replacement medication.